Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chymotrypsin + diclofenac potassium + trypsin
- Development stage
- Unknown
- Lead developer
- Zinnia Life Sciences
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
ChymoBest-D is an oral fixed-dose combination tablet containing the proteolytic enzymes trypsin and chymotrypsin alongside the nonsteroidal anti-inflammatory drug (NSAID) diclofenac potassium. Developed by Zinnia Life Sciences, this formulation is designed to provide synergistic anti-inflammatory, analgesic, and anti-edematous effects. Diclofenac potassium acts as a fast-acting NSAID that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby alleviating pain and inflammation. Trypsin and chymotrypsin are proteolytic enzymes that facilitate tissue repair, break down inflammatory debris, and reduce localized edema and swelling. ChymoBest-D is primarily indicated for the management of pain, swelling, and inflammation associated with musculoskeletal disorders, joint diseases (such as osteoarthritis and rheumatoid arthritis), post-traumatic injuries, and post-operative recovery.
- Brand names
- ChymoBest-D
- Other names
- chymotrypsin + diclofenac + trypsinchymotrypsin + diclofenac potassium + trypsindiclofenac + trypsin-chymotrypsindiclofenac potassium + trypsin-chymotrypsintrypsin-chymotrypsin + diclofenactrypsin-chymotrypsin + diclofenac potassium
02
Targets
CTRC (Chymotrypsin C)Fibrin (Factor Ia)PRSS1 (Trypsin family)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on chymotrypsin + diclofenac potassium + trypsin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chymotrypsin + diclofenac potassium + trypsin.